Display options
Cite
Gangadhara S, Kwon YM, Jeeva S, et al. Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins. Vaccines (Basel). 2017;5(4)doi: 10.3390/vaccines5040052.
Gangadhara, S., Kwon, Y. M., Jeeva, S., Quan, F. S., Wang, B., Moss, B., Compans, R. W., Amara, R. R., Jabbar, M. A., & Kang, S. M. (2017). Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins. Vaccines, 5(4), . https://doi.org/10.3390/vaccines5040052
Gangadhara, Sailaja, et al. "Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins." Vaccines vol. 5,4 (2017). doi: https://doi.org/10.3390/vaccines5040052
Gangadhara S, Kwon YM, Jeeva S, Quan FS, Wang B, Moss B, Compans RW, Amara RR, Jabbar MA, Kang SM. Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins. Vaccines (Basel). 2017 Dec 19;5(4). doi: 10.3390/vaccines5040052. PMID: 29257056; PMCID: PMC5748618.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2017 Dec 19;5(4). doi: 10.3390/vaccines5040052.

Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins.

Vaccines

Sailaja Gangadhara, Young-Man Kwon, Subbiah Jeeva, Fu-Shi Quan, Baozhong Wang, Bernard Moss, Richard W Compans, Rama Rao Amara, M Abdul Jabbar, Sang-Moo Kang

Affiliations

  1. Department of Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, USA. [email protected].
  2. Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA. [email protected].
  3. Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA. [email protected].
  4. Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul 130-705, Korea. [email protected].
  5. Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA. [email protected].
  6. Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. [email protected].
  7. Department of Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, USA. [email protected].
  8. Department of Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, USA. [email protected].
  9. Department of Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, USA. [email protected].
  10. Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA. [email protected].

PMID: 29257056 PMCID: PMC5748618 DOI: 10.3390/vaccines5040052

Abstract

Heterologous prime boost with DNA and recombinant modified vaccinia virus Ankara (rMVA) vaccines is considered as a promising vaccination approach against human immunodeficiency virus (HIV-1). To further enhance the efficacy of DNA-rMVA vaccination, we investigated humoral and cellular immune responses in mice after three sequential immunizations with DNA, a combination of DNA and virus-like particles (VLP), and rMVA expressing HIV-1 89.6 gp120 envelope proteins (Env). DNA prime and boost with a combination of VLP and DNA vaccines followed by an rMVA boost induced over a 100-fold increase in Env-specific IgG antibody titers compared to three sequential immunizations with DNA and rMVA. Cellular immune responses were induced by VLP-DNA and rMVA vaccinations at high levels in CD8 T cells, CD4 T cells, and peripheral blood mononuclear cells secreting interferon (IFN)-γ, and spleen cells producing interleukin (IL)-2, 4, 5 cytokines. This study suggests that a DNA and VLP combination vaccine with MVA is a promising strategy in enhancing the efficacy of DNA-rMVA vaccination against HIV-1.

Keywords: DNA; HIV vaccines; VLPs; recombinant MVA

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. J Infect Dis. 2011 Mar 1;203(5):610-9 - PubMed
  2. J Virol. 1998 Oct;72(10):8264-72 - PubMed
  3. PLoS One. 2010 Jan 25;5(1):e8816 - PubMed
  4. Virology. 2004 Feb 20;319(2):176-84 - PubMed
  5. J Exp Med. 2008 Jan 21;205(1):7-12 - PubMed
  6. AIDS. 1999;13 Suppl A:S121-36 - PubMed
  7. J Immunol. 2001 May 1;166(9):5346-55 - PubMed
  8. Annu Rev Immunol. 2000;18:927-74 - PubMed
  9. J Immunol. 2003 Sep 1;171(5):2242-50 - PubMed
  10. Vaccine. 2007 May 10;25(19):3841-50 - PubMed
  11. J Infect Dis. 1987 Dec;156(6):878-84 - PubMed
  12. J Virol. 2005 Sep;79(17):10902-14 - PubMed
  13. J Virol. 2006 Sep;80(18):9134-43 - PubMed
  14. Science. 1999 Feb 5;283(5403):857-60 - PubMed
  15. J Biomed Biotechnol. 2010;2010:497219 - PubMed
  16. J Infect Dis. 2014 Jul 1;210(1):99-110 - PubMed
  17. J Virol. 2007 Apr;81(7):3487-94 - PubMed
  18. Vaccine. 2007 Aug 10;25(32):5968-77 - PubMed
  19. J Virol. 2015 Apr;89(8):4690-5 - PubMed
  20. J Virol. 2016 Sep 12;90(19):8842-54 - PubMed
  21. Virol J. 2009 Aug 12;6:123 - PubMed
  22. J Immunol. 2003 Mar 1;170(5):2496-507 - PubMed
  23. Immunol Today. 1996 May;17(5):217-24 - PubMed
  24. AIDS Res Hum Retroviruses. 2004 Dec;20(12):1335-47 - PubMed
  25. J Virol. 2009 May;83(9):4489-97 - PubMed
  26. Virology. 2007 Sep 15;366(1):73-83 - PubMed
  27. Nat Med. 1999 Feb;5(2):194-203 - PubMed
  28. Virology. 2010 Sep 15;405(1):165-75 - PubMed
  29. Trends Microbiol. 2008 Dec;16(12):605-11 - PubMed
  30. AIDS. 1989 May;3(5):273-6 - PubMed
  31. Vaccine. 2007 Apr 12;25(15):2951-8 - PubMed
  32. Nat Med. 2008 Jun;14(6):617-21 - PubMed
  33. J Immunol. 2016 Nov 1;197(9):3586-3596 - PubMed
  34. J Virol. 2009 May;83(9):4102-11 - PubMed
  35. J Virol. 2002 Aug;76(15):7625-31 - PubMed
  36. Virology. 2006 Sep 1;352(2):285-94 - PubMed
  37. Hum Vaccin. 2010 Oct;6(10):835-40 - PubMed
  38. Virology. 2007 Jun 5;362(2):331-41 - PubMed
  39. Vaccine. 2004 Nov 25;23(2):139-47 - PubMed
  40. PLoS One. 2009 Sep 25;4(9):e7152 - PubMed
  41. Open Forum Infect Dis. 2016 Feb 11;3(1):ofw034 - PubMed
  42. N Engl J Med. 2009 Dec 3;361(23):2209-20 - PubMed
  43. Gene Ther. 2004 Apr;11(7):628-35 - PubMed
  44. Virology. 2004 Sep 1;326(2):280-7 - PubMed
  45. Proc Natl Acad Sci U S A. 1988 May;85(9):3105-9 - PubMed
  46. Virology. 2007 Dec 5;369(1):153-67 - PubMed
  47. Nat Med. 2004 Mar;10(3):221-3 - PubMed
  48. Vaccine. 2002 May 6;20(15):1995-8 - PubMed
  49. Vaccines (Basel). 2014 Feb 28;2(1):160-78 - PubMed

Publication Types

Grant support